Reimbursement
Value-based care demands the switch to wellcare to raise outcomes and decrease costs, Claire Pomeroy says.
There's a whole lot of finger pointing happening among feds, providers, payers, pharmacy benefits managers and big pharma, in what HHS Secretary Azar called the "dirty, little secret of drug pricing."
Implementation of these programs was not associated with reductions in device-associated CAUTI rates.
Data shows slow industry adoption, as close to 42 percent of respondents said their virtual care solution did not integrate with their EHR.
HIMSS19: Leveraging technology to improve prior authorization...
Finance leaders are worried about the changing landscape, and many feel unprepared for what's to come.
Under the proposal, drugs would be chosen that have the lowest price, not the ones that offer the highest rebate.
The settlement also requires Aetna to implement mailing procedures that protect the confidentiality of medical information and complete a yearly compliance assessment.
CMS had hoped the threat of penalties would focus more attention on improving care quality, but most of the changes have been to coding practices.
For the first time, MA plans may lower cost sharing for drugs such as Naloxone, to treat opioid overdoses.